Literature DB >> 9845611

Surgical treatment of locally advanced rectal cancer. Options and strategies.

M Aleksic1, N Hennes, B Ulrich.   

Abstract

AIMS: The results of surgical treatment of locally advanced rectal cancer with special regard to multivisceral resections and preoperative radiotherapy should be analyzed.
METHODS: From 10/86 until 12/95, 40 patients with preoperatively assessed T4 stage rectal cancer were treated in our department whose data were evaluated retrospectively.
RESULTS: Apart from 10 nonresecting procedures we performed 30 resections in which the mortality rate was 7%. In 50% of these patients a multivisceral resection was conducted. A R0 situation could be achieved in 70%. But only in 53% the operation was carried out with curative approach due to distant metastasis. After extended resections more frequent urological complications resulted in prolonged hospitalization. Survival time was markedly longer in patients without tumor residuals or metastasis. Following preoperative radiotherapy a higher number in tumor free patients and better prognosis was noticed.
CONCLUSIONS: In accordance to the literature it is suggested to submit patients with T4-stage rectal cancer to preoperative radiation to improve the overall outcome.

Entities:  

Mesh:

Year:  1998        PMID: 9845611     DOI: 10.1159/000018629

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  2 in total

1.  Outcome of surgical management of the bladder in advanced colorectal cancer.

Authors:  Feng Gao; Yun-fei Cao; Li-sheng Chen; Sen Zhang; Zong-jiang Tang; Jun-lin Liang
Journal:  Int J Colorectal Dis       Date:  2006-03-01       Impact factor: 2.571

2.  Sphincter-preserving R0 total mesorectal excision with resection of internal genitalia combined with pre- or postoperative chemoradiation for T4 rectal cancer in females.

Authors:  Bartlomiej Szynglarewicz; Rafal Matkowski; Piotr Kasprzak; Daniel Sydor; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.